ABT – abbott laboratories (US:NYSE)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

ABT

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

4/17

01:04 pm

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

01:04 pm

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

12:09 pm

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

12:09 pm

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

11:46 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

11:46 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

11:35 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

11:35 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

11:06 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

11:06 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

09:04 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

08:43 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

4/17

08:43 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

3/4

12:19 pm

abt

Rating for ABT

Low Report

Rating for ABT

Report

3/4

12:19 pm

abt

Rating for ABT

Low Report

Rating for ABT

Report

3/4

08:59 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

3/4

08:59 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

3/4

08:59 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

1/31

07:00 am

abt

Abbott Laboratories (NYSE: ABT) was upgraded by analysts at Argus to a "strong-buy" rating.

Low Report

Abbott Laboratories (NYSE: ABT) was upgraded by analysts at Argus to a "strong-buy" rating.

Report

1/31

07:00 am

abt

Abbott Laboratories (NYSE: ABT) was upgraded by analysts at Argus to a "strong-buy" rating.

Low Report

Abbott Laboratories (NYSE: ABT) was upgraded by analysts at Argus to a "strong-buy" rating.

Report

1/27

08:01 am

abt

Abbott Laboratories (NYSE: ABT) had its "overweight" rating re-affirmed by analysts at Barclays PLC. They now have a $158.00 price target on the stock, up previously from $149.00.

Medium Report

Abbott Laboratories (NYSE: ABT) had its "overweight" rating re-affirmed by analysts at Barclays PLC. They now have a $158.00 price target on the stock, up previously from $149.00.

Report

1/27

06:29 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

1/27

06:29 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

1/23

11:43 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

1/23

11:43 am

abt

Rating for ABT

Low Report

Rating for ABT

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.